Compare CBAT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBAT | SERA |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Precision Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 90.6M |
| IPO Year | N/A | 2021 |
| Metric | CBAT | SERA |
|---|---|---|
| Price | $0.89 | $3.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 120.7K | 33.2K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,757,685.00 | $95,000.00 |
| Revenue This Year | $16.06 | $19.22 |
| Revenue Next Year | $70.59 | $400.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $0.57 | $1.37 |
| 52 Week High | $1.28 | $9.13 |
| Indicator | CBAT | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 48.25 |
| Support Level | $0.86 | $2.81 |
| Resistance Level | $0.91 | $3.14 |
| Average True Range (ATR) | 0.03 | 0.26 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 43.42 | 34.67 |
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.